SpringWorks Therapeutics
100 Washington Blvd
Stamford
Connecticut
06902
United States
Website: http://www.springworkstx.com/
Email: Media@springworkstx.com
About SpringWorks Therapeutics
30 articles with SpringWorks Therapeutics
-
BioSpace Global Roundup, Sept. 26
9/26/2019
Companies from across the globe share updates on their business and pipelines. -
European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma
9/25/2019
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of soft tissue sarcoma.
-
SpringWorks Therapeutics Announces Pricing Of Initial Public Offering
9/12/2019
SpringWorks Therapeutics, Inc. announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $18.00 per share.
-
SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid Tumors
8/29/2019
SpringWorks Therapeutics, Inc. announced the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.
-
BioSpace Movers & Shakers, Aug. 16
8/16/2019
Biopharma companies strengthen their executive ranks and boards with new additions. -
SpringWorks Therapeutics Announces Appointment of Frank Perier as Chief Financial Officer
8/15/2019
SpringWorks Therapeutics, Inc. announced the appointment of Francis (Frank) Perier, Jr. as Chief Financial Officer (CFO).
-
BioSpace Global Roundup, Aug. 8
8/8/2019
Biopharma companies from across the globe share business and development updates. -
European Commission Grants Orphan Drug Designation for SpringWorks Therapeutics’ MEK Inhibitor, Mirdametinib, for the Treatment of Neurofibromatosis Type 1
7/30/2019
SpringWorks Therapeutics, Inc. announced that the European Commission has granted Orphan Drug Designation for mirdametinib, an oral, small molecule inhibitor of MEK1 and MEK2, for the treatment of neurofibromatosis type 1.
-
SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma
6/27/2019
SpringWorks Therapeutics, Inc. announced that the company has entered into a clinical trial collaboration agreement with GlaxoSmithKline to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat, in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen antibody-drug conjugate, belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.
-
The companies will combine their research expertise to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations, non-V600 B-RAF mutations, and RAF fusions.
-
BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor
6/18/2019
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the formation of MapKure, LLC,
-
SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1
6/3/2019
SpringWorks Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for PD-0325901, an investigational, oral, small molecule inhibitor of MEK1 and MEK2, for the treatment of patients ≥ 2 years of age with neurofibromatosis type 1-associated inoperable plexiform neurofibromas that are progressing or causing significant morbidity.
-
SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors
5/20/2019
SpringWorks Therapeutics announced that the first patient has been dosed in the Phase 3 “DeFi” trial evaluating nirogacestat, an oral, selective, small molecule gamma-secretase inhibitor, in adult patients with progressing desmoid tumors.
-
SpringWorks Therapeutics Announces Initiation of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901 in Combination with BeiGene’s RAF Dimer Inhibitor Lifirafenib in Advanced or Refractory Solid Tumors
5/6/2019
SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in a Phase 1b study to evaluate the combination of SpringWorks Therapeutics’ investigational MEK inhibitor, PD-0325901, and BeiGene, Ltd.’s investigational RAF dimer inhibitor, lifirafenib, in patients with advanced or refractory solid tumors.
-
SpringWorks Therapeutics Completes $125 Million Series B Financing
4/1/2019
Three Clinical Trials Expected to Commence in the First Half of 2019, Including Two Late-Stage Rare Oncology Programs and First Targeted Oncology Program in Collaboration with BeiGene
-
The late-stage studies funded by the financing round could set the stage for two potential regulatory approvals if the data remains strong.
-
SpringWorks Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference
3/4/2019
SpringWorks Therapeutics announced that Saqib Islam, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference in Boston on Tuesday, March 12, 2019, at 3:30 p.m. Eastern Standard Time.
-
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
-
SpringWorks Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
12/20/2018
SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2019, at 10:30 a.m. Pacific Standard Time.
-
SpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid Tumors
11/7/2018
SpringWorks Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for nirogacestat, an investigational, oral, small molecule, selective gamma-secretase inhibitor, for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.